Introduction {#s1}
============

Worldwide, there are over 300 million people with a diagnosis of asthma \[[@C1]\], and this number is predicted to increase to at least 400 million by the year 2025 \[[@C2]\]. Despite the use of inhaled corticosteroids (ICS) combined with other drugs as standard of care \[[@C3]\], many patients have asthma that requires either treatment with high-dose ICS plus a second controller, or the addition of systemic corticosteroids to gain control; these patients are considered to have severe asthma \[[@C4]\].

Patients who have severe asthma with an eosinophilic phenotype, as characterised by elevated blood and/or sputum eosinophil counts, have increased exacerbation rates, impaired lung function, poorer symptom control and lower quality of life (QoL) compared with patients with non-eosinophilic asthma \[[@C5]\]. Blood eosinophil counts ≥400 cells·μL^−1^ have a proven association with increased frequency and severity of clinical asthma exacerbations (CAEs) and poor asthma control \[[@C6]\]. This has led to the development of novel therapies that target the molecular regulators of eosinophil function in asthma pathophysiology.

Interleukin-5 (IL-5) is the key regulator of eosinophil maturation, mobilisation from the bone marrow and recruitment to sites of inflammation \[[@C7], [@C8]\]. Reslizumab, an intravenously administered humanised anti-IL-5 monoclonal antibody, has been developed to inhibit the pro-inflammatory action of IL-5 on eosinophils \[[@C9]--[@C11]\].

Reslizumab has been approved in the USA, the EU and Canada as add-on maintenance treatment of patients aged 18 years and older with severe eosinophilic asthma \[[@C12]--[@C14]\]. Owing to insufficient clinical data in patients aged \<18 years, reslizumab is not currently approved for use in children (aged ≤11 years) or adolescent patients (aged 12--17 years) \[[@C12], [@C13]\].

The efficacy and safety of reslizumab *versus* placebo have been demonstrated in duplicate placebo-controlled Phase III studies, in patients with inadequately controlled asthma and elevated blood eosinophils (≥400 cells·μL^−1^) who were aged 12--75 years \[[@C9]\]. For inclusion in these studies, eligible patients were receiving at least a medium dose of ICS (≥440 μg·day^−1^ fluticasone proprionate, or equivalent) with or without another controller drug (long-acting β~2~ agonist (LABA), oral corticosteroids (OCS), leukotriene receptor inhibitors (LTRI), lipoxygenase inhibitors or cromolyn sodium) \[[@C9]\], representing Step 3--5 treatment according to the Global Initiative for Asthma (GINA) guidelines \[[@C15]\].

Data from both studies demonstrated that, compared with placebo, reslizumab significantly reduced the annual frequency of asthma exacerbations by 54% (pooled data, p\<0.0001), and reduced the occurrence of CAEs requiring at least 3 days of OCS use by 57% (p\<0.0001) with a safety profile comparable to that of placebo \[[@C9]\]. Reslizumab treatment also rapidly improved lung function, with patients showing significant improvements in forced expiratory volume in 1 s (FEV~1~) at the first on-study assessment (week 4) (p\<0.05) that were sustained throughout the study \[[@C9]\]. Patient-reported outcomes (Asthma Control Questionnaire-7 (ACQ-7) and Asthma Quality of Life Questionnaire (AQLQ) scores) were also significantly improved from first on-study assessment throughout the study, demonstrating increased control of symptoms and improved QoL \[[@C9]\].

We performed a secondary analysis of the Phase III data to determine the efficacy of reslizumab as add-on therapy in patients receiving asthma treatment per Step 4 and Step 5 of the GINA guidelines at baseline.

Patients and methods {#s2}
====================

Both studies included in this analysis were Phase III, international, randomised, double-blind, parallel-group, placebo-controlled studies to assess the efficacy and safety of reslizumab (3 mg·kg^−1^ *i.v.* every 4 weeks) compared with placebo. These studies have been published previously \[[@C9]\].

In brief, both studies enrolled patients with inadequately controlled asthma (ACQ-7 score of ≥1.5) \[[@C16]\]. Current smokers (within the previous 6 months) were excluded. Patients were aged 12--75 years with eosinophilic asthma, defined as at least one blood eosinophil count of ≥400 cells·μL^−1^ during a 2--4-week screening period.

Eligible patients received medium-to-high dose ICS at baseline (fluticasone propionate ≥440 μg·day^−1^, or equivalent) with or without another controller (including OCS). Patients continued to use their GINA Step 4 or Step 5 asthma treatment, including any add-on therapy, throughout the study. The use of omalizumab or other biologic therapy was not permitted.

Eligible patients were also required to have had at least one exacerbation requiring the use of systemic corticosteroids for ≥3 days within the 12 months before screening and have an FEV~1~ reversibility of ≥12% with salbutamol.

Patients were randomised 1:1 to receive either reslizumab 3 mg·kg^−1^ *i.v.* every 4 weeks for 13 doses, or matching placebo.

The primary endpoint of both studies was the annual CAE frequency and secondary endpoints included change from baseline FEV~1~, ACQ-7 score and AQLQ score \[[@C9]\].

Both studies were conducted according to Good Clinical Practice guidelines, the Declaration of Helsinki and local regulatory requirements. Relevant health authorities and local ethics committees or institutional review boards approved the study protocols, and all patients provided written informed consent.

Statistical analyses {#s2a}
--------------------

Patients were stratified into GINA Step 4 and Step 5 groups based on their baseline medications at the time they were randomised to treatment arms in the duplicate studies. Patients comprising the Step 4 group were defined as receiving ≥2 controllers (medium-to-high dose ICS plus a LABA or LTRI) plus as-needed reliever medication; the Step 5 group was defined as receiving add-on treatment with OCS. Patients with insufficient information on their baseline medication were excluded from these analyses to ensure the integrity of the Step 4 and Step 5 subsets.

All efficacy endpoints were assessed in the intent-to-treat population (all randomised patients aged 12--75 years). CAE frequency was analysed using a negative binomial regression model as previously described \[[@C9]\]. Rate ratios (RRs) *versus* placebo (with 95% CIs) were estimated using the same model.

The secondary endpoints were analysed using mixed models for repeated measures with treatment, study visit, treatment by visit interaction and stratification factors as fixed factors, and covariates for baseline value and patient as a random effect. For pulmonary function endpoints, the model also included sex and height.

The proportions of patients achieving a clinically meaningful improvement in AQLQ or ACQ-7 scores (a ≥0.5-point change in score) \[[@C17], [@C18]\] were analysed using a stratified Cochran--Mantel--Haenszel test. Data were pooled from both studies to perform subgroup analyses for primary and secondary endpoints.

Further sub-analyses were performed based on the types and doses of medications received at baseline. In the GINA Step 4 group, only 11 patients were receiving ICS and LTRI at baseline (seven in the placebo group and four in the reslizumab group); because of the limited data available for this subgroup, meaningful statistics for CAEs, FEV~1~ and patient-reported outcomes could not be calculated.

Results {#s3}
=======

Patient population {#s3a}
------------------

Patient demographics and clinical characteristics are summarised in [table 1](#TB1){ref-type="table"}. In general, baseline demographics were well balanced across placebo and reslizumab groups within the Step 4 and Step 5 populations. At baseline, more patients were receiving Step 4 treatment (n=657) than Step 5 treatment (n=106). Patients in the Step 4 group were slightly younger than those in the Step 5 group: median ages were 48 and 52 years, respectively. Only 19 patients aged 12--17 years were receiving Step 4 (placebo n=7; reslizumab n=11) or Step 5 therapy (placebo n=1) at baseline. In both Step 4 and Step 5 groups, a greater proportion of patients were female: 63% and 58%, respectively. Compared with patients receiving Step 4 treatment, a higher proportion of Step 5 patients were of white race (92% *versus* 75%).

###### 

Baseline demographics and characteristics for randomised patients: Global Initiative for Asthma (GINA) Step 4 and GINA Step 5

                                                                                 **GINA Step 4**        **GINA Step 5**                                                                       
  --------------------------------------------------------------------------- ---------------------- ---------------------- ------------------- ---------------------- ---------------------- -------------------
  **Patients n**                                                                       322                    335                   657                   58                     48                   106
  **Age years median (interquartile range)**                                    48.0 (12.0--74.0)      48.0 (12.0--75.0)     48.0 (12.0--75.0)    52.0 (16.0--75.0)      52.5 (20.0--69.0)     52.0 (16.0--75.0)
  **Male**                                                                           107 (33)               133 (40)             240 (37)              23 (40)                22 (46)               45 (42)
  **Race**                                                                                                                                                                                    
   White                                                                             241 (75)               250 (75)             491 (75)              55 (95)                43 (90)               98 (92)
   Black                                                                              13 (4)                 12 (4)               25 (4)                1 (2)                  1 (2)                 2 (2)
   Asian                                                                             46 (14)                46 (14)               92 (14)               2 (3)                  4 (8)                 6 (6)
   Other                                                                              22 (7)                 27 (8)               49 (7)                  0                      0                     0
  **BMI kg·m^−2^, mean±[sd]{.smallcaps}**                                           27.5±5.62              27.3±5.68             27.4±5.65            26.9±5.23              27.5±5.92             27.2±5.54
  **Patients with atopic history**                                                   211 (66)               212 (63)             423 (64)              37 (64)                27 (56)               64 (60)
  **Patients with seasonal allergies^\#^**                                           103 (64)               89 (52)              192 (58)              14 (35)                 8 (33)               22 (34)
  **CAEs in the 12** **months prior to enrolment n, mean±[se]{.smallcaps}**          1.8±0.08               1.8±0.08             1.8±0.06              3.4±0.46               2.6±0.37             3.0±0.30
  **OCS use at enrolment per IVRS**                                                     0                      0                     0                 58 (100)               48 (100)             106 (100)
  **FEV**~**1**~ **L**                                                         1.820 (0.340--4.680)   1.920 (0.550--4.570)          --           1.650 (0.540--3.930)   1.485 (0.640--3.310)          --
  **ACQ-7 score**                                                              2.571 (0.143--5.429)   2.429 (0.429--5.000)          --           3.071 (1.143--5.571)   3.214 (1.286--5.286)          --
  **AQLQ score**                                                               4.156 (1.406--7.000)   4.469 (1.719--6.969)          --           3.906 (1.656--6.125)   3.797 (1.750--6.250)          --

Data are presented as n (%) or median (range), unless otherwise stated. BMI: body mass index; CAE: clinical asthma exacerbation; OCS: oral corticosteroids; IVRS: interactive voice response system; FEV~1~: forced expiratory volume in 1 s; ACQ-7: asthma control questionnaire-7; AQLQ: asthma quality of life questionnaire. ^\#^: Data for patients with seasonal allergies only available for Study 2.

In line with more severe disease in patients receiving GINA Step 5 treatment, baseline lung function and patient-reported outcome data differed between the Step 4 and Step 5 populations. FEV~1~ values and AQLQ scores were lower in the Step 5 group compared with the Step 4 group, whereas ACQ-7 scores were higher in the Step 5 group, implying worse asthma control. In the Step 5 group, patients received oral corticosteroids at a mean±[sd]{.smallcaps} dose (prednisone or equivalent) of 8.2±7.65 mg in the placebo arm and 7.1±2.84 mg in the reslizumab arm.

Clinical asthma exacerbations {#s3b}
-----------------------------

Compared with placebo, reslizumab add-on therapy reduced the adjusted CAE rate in Step 4 and Step 5 populations by 53% (RR 0.47; 95% CI 0.36--0.62) and 72% (RR 0.28; 95% CI 0.15--0.52), respectively ([fig. 1a](#F1){ref-type="fig"}).

![Effects of reslizumab on: (a) clinical asthma exacerbation (CAE) rates; (b) rates of clinical asthma exacerbation requiring oral corticosteroids (OCS); and (c) rates of CAEs requiring hospitalisation or an emergency room visit, in Global Initiative for Asthma (GINA) Step 4 and 5 patients.](00004-2017.01){#F1}

An analysis of the Step 4 subpopulation by baseline medication demonstrated that reslizumab reduced CAE rates by 61% (RR 0.39; 95% CI 0.27--0.58) and 43% (RR 0.57; 95% CI 0.39--0.86) in patients receiving medium-dose and high-dose ICS/LABA at baseline, respectively. This difference may be due to the higher efficacy of high-dose ICS/LABA in prevention of exacerbations.

During the study, exacerbations requiring intervention with either systemic corticosteroids, hospitalisation or a visit to the emergency room occurred in a total of 272 patients (174 in the placebo group and 98 in the reslizumab group). Compared with placebo, reslizumab significantly reduced the rate of CAE requiring OCS by 56% in the Step 4 group (RR 0.44; 95% CI 0.32--0.60) and by 72% in the Step 5 group (RR 0.28; 95% CI 0.14--0.55) ([fig. 1b](#F1){ref-type="fig"}).

Because of the low number of patients aged 12--17 years in the pivotal studies (Step 4: placebo n=7, reslizumab n=11; Step 5: placebo n=1), the effects of reslizumab treatment on healthcare resource utilisation, hospitalisation or a visit to the emergency room due to a CAE were assessed only in adult patients (aged ≥18 years). Reslizumab reduced the rate of CAE-related hospitalisations and visits to the emergency room by 50% (95% CI 0.25--0.97) compared with placebo ([fig. 1c](#F1){ref-type="fig"}). This effect was greater in patients who had experienced ≥2 exacerbations in the previous year, with reslizumab reducing the exacerbation-related hospitalisation/emergency room visit rate by 72% (95% CI 0.11--0.72) ([fig. 1c](#F1){ref-type="fig"}).

Lung function {#s3c}
-------------

In GINA Step 4 and Step 5 groups, reslizumab increased FEV~1~ compared with placebo at weeks 16 and 52 ([fig. 2a](#F2){ref-type="fig"}). At week 16, reslizumab increased FEV~1~ by 114 mL and 271 mL compared with placebo in the Step 4 and Step 5 populations, respectively. Similar improvements were observed at week 52, with FEV~1~ increases of 103 mL and 237 mL in the Step 4 and Step 5 populations, respectively. Reslizumab increased FEV~1~ as early as the first study assessment, at week 4, and the FEV~1~ improvement was sustained throughout treatment ([fig. 2b](#F2){ref-type="fig"}).

![Effects of reslizumab on lung function (forced expiratory volume in 1 s; FEV~1~) in Global Initiative for Asthma (GINA) Step 4 and 5 patients. (a) Changes from baseline FEV~1~ at week 16 and week 52 and (b) changes relative to placebo throughout the study. LS: least square.](00004-2017.02){#F2}

Analyses of FEV~1~ by baseline therapy in the Step 4 subgroup demonstrated that reslizumab improved FEV~1~, regardless of the intensity of baseline ICS/LABA therapy. At week 16, reslizumab increased FEV~1~ by 101 mL (95% CI 36--165) in the medium-dose ICS/LABA group and by 132 mL (95% CI 46--219) in the high-dose ICS/LABA group. Data at week 52 were generally consistent with those at week 16, with increases of 96 mL (95% CI 30--162) and 118 mL (95% CI 35--201) in the medium-dose and high-dose ICS/LABA groups, respectively.

In Step 4 patients, mean forced vital capacity (FVC) increased between baseline and the end of treatment in both arms, with a larger increase in the reslizumab arm (220 mL, from 3.091 L to 3.320 L) compared with the placebo arm (117 mL, from 2.965 L to 3.091 L). In Step 5 patients mean FVC improved by 429 mL in the reslizumab arm (from 2.768 L to 3.197 L) and by 111 mL in the placebo arm (from 2.964 L to 3.094 L). Median FEV~1~/FVC ratio in Step 4 patients was 65.5% at baseline and 67.6% at the end of treatment in the reslizumab arm *versus* 65.9% (baseline) and 66.4% (end of treatment) in the placebo arm. In Step 5 patients median FEV~1~/FVC ratios were 62.2% (baseline) and 65.0% (end of treatment) in the reslizumab arm *versus* 61.2% (baseline) and 65.0% (end of treatment) in the placebo arm.

Patient-reported outcomes {#s3d}
-------------------------

### Control of symptoms {#s3d1}

Asthma control, as assessed using the ACQ-7 questionnaire, was improved with reslizumab in Step 4 and Step 5 patient groups ([fig. 3a](#F3){ref-type="fig"}).

![Effects of reslizumab on asthma control questionnaire-7 (ACQ-7) score in Global Initiative for Asthma (GINA) Step 4 and 5 patients. (a) Changes from baseline ACQ-7 score at week 16 and week 52 and (b) changes relative to placebo throughout the study. Increase in control is represented by a decrease in ACQ-7 score \[[@C16], [@C19]\]. LS: least square.](00004-2017.03){#F3}

Compared with placebo, reslizumab improved asthma control, reducing the ACQ-7 scores by --0.333 (95% CI −0.438-- −0.227) and −0.192 points (95% CI −0.564-- −0.179) at week 16 and by −0.330 (95% CI −0.435-- −0.224) and −0.247 points (95% CI −0.679, 0.136) at week 52 in the Step 4 and Step 5 groups, respectively ([fig. 3a](#F3){ref-type="fig"}). Improved asthma control with reslizumab was demonstrated throughout therapy, from the week 4 assessment until the end of the study ([fig. 3b](#F3){ref-type="fig"}).

Analyses of asthma control with reslizumab by Step 4 baseline therapy are shown in supplementary table S1.

Responder analyses were performed for ACQ-7-evaluable adult patients only, owing to the low number of adolescent patients. A higher proportion of those patients receiving reslizumab had a clinically meaningful improvement in ACQ-7 score (a decrease in score ≥0.5) \[[@C17], [@C19]\] compared with placebo at week 16 (66% *versus* 55%) and week 52 (80% *versus* 61%).

### Quality of life {#s3d2}

Compared with placebo, reslizumab improved QoL in Step 4 and Step 5 patients when assessed at weeks 16, 32 and 52 ([fig. 4](#F4){ref-type="fig"}).

![Effects of reslizumab on asthma quality of life questionnaire (AQLQ) score in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Changes from baseline AQLQ score at week 16, week 32 and week 52. Increased quality of life is represented by increased AQLQ score. The first post-baseline measurement for AQLQ was at week 16. LS: least square.](00004-2017.04){#F4}

Analyses of AQLQ scores by baseline GINA Step 4 therapy are shown in supplementary table S2. Responder analyses were performed for adult patients only. Of the evaluable patients, a higher proportion of those receiving reslizumab had a clinically meaningful improvement in AQLQ score (≥0.5 increase in score) compared with placebo at week 16 (63% *versus* 54%) and week 52 (74% *versus* 63%).

Discussion {#s4}
==========

The results of this analysis highlight that intravenous reslizumab, given as a 3 mg·kg^−1^ dose every 4 weeks, improves outcomes in patients with severe eosinophilic asthma in terms of exacerbations, lung function and patient-reported outcomes. These benefits can be seen in patients requiring either GINA Step 4 or Step 5 therapy. Patients requiring Step 5 therapy, by definition, have more severe asthma and are more likely to experience a CAE than patients at Step 4. In the previous publication, data were presented for the overall patient populations including Step 3, Step 4 and Step 5 patients. The data from our sub-analyses clearly show that, in adult patients with severe eosinophilic asthma, reslizumab reduces the CAE rate in Step 4 and Step 5 treatment groups, with the most pronounced reduction occurring in the Step 5 group.

In general, the magnitude of the improvements in CAE rate and FEV~1~ with reslizumab *versus* placebo was greater in the Step 5 group than the Step 4 group, which might be attributed to the severity of their disease and the potential room for improvement in patients requiring Step 5 treatment. The Step 5 patient population may represent the proposed T-helper-2-high asthma endotype that is characterised by severe asthma, with airway and systemic eosinophilia, responsiveness to glucocorticoids and inhibitors of type-2 inflammation, such as IL-5 \[[@C20]\]. Such a population is likely to be highly responsive to immune-directed therapies that target regulators of eosinophil function.

In terms of exacerbations, not only did reslizumab reduce the rate of exacerbations in both groups, it also reduced the occurrence of the most severe exacerbations requiring healthcare utilisation. The use of a therapy that reduces the exposure to OCS and the need for hospitalisation/admission has the potential to decrease the burdens placed on patients with uncontrolled severe asthma and the emergency departments treating them.

Interestingly, the QoL benefits provided by reslizumab are comparable in Step 4 and Step 5 groups, despite the differences in CAE, FEV~1~ and ACQ endpoints in Step 4 and Step 5 groups. Approximately 40% of patients in the study populations have no history of atopy and 42% and 66% in Step 4 and Step 5 groups, respectively, are not allergic ([table 1](#TB1){ref-type="table"}). The improvements in QoL seen upon treatment with reslizumab may not be fully captured by the AQLQ.

Phase III studies of other antibodies targeting IL-5 or its receptor have also demonstrated reductions in exacerbation rates and improvements in lung function \[[@C21]--[@C23]\]. Treatment with the anti-IL-5 antibody mepolizumab subcutaneously or intravenously for 32 weeks resulted in a 47--53% reduction in the rate of asthma exacerbations compared with placebo in 576 patients with recurrent exacerbations and evidence of eosinophilic inflammation. The mean increase in FEV~1~ was also 98--100 mL greater in mepolizumab-treated patients \[[@C21]\]. Similarly, two Phase III trials of the anti-IL-5 receptor antibody benralizumab have reported comparable reductions in exacerbation rates and improvements in FEV~1~ after 48--56 weeks' treatment every 4 or 8 weeks \[[@C22], [@C23]\]. These data support the use of therapies targeting IL-5 stimulation in treatment of asthma in patients with elevated eosinophil levels, though differences in patient characteristics, eosinophil levels and trial design preclude direct comparison between trials. Also, efficacy of benralizumab and mepolizumab specifically in Step 4 and Step 5 patients is not reported in these studies. Overall, the data from our sub-analyses are consistent with those previously published for Phase III clinical studies of reslizumab and add to the body of evidence demonstrating the efficacy of reslizumab in patients with severe eosinophilic asthma \[[@C9]--[@C11]\].

Based on these data, we conclude that reslizumab reduces exacerbation rates and improves lung function and patient-reported outcomes in adult patients with eosinophilic asthma receiving therapy according to GINA Step 4 and 5.
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